Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fatrovax RHD is a **veterinary recombinant inactivated rabbit haemorrhagic disease vaccine** for rabbits, including pet and dwarf rabbits. It is developed and marketed by Fatro and is authorized in the European Union for active immunization from 28 days of age to reduce mortality, infection, clinical signs, and organ lesions caused by **rabbit haemorrhagic disease virus 1 and 2**. The vaccine contains two recombinant capsid protein antigens that assemble into **virus-like particles** representing RHDV1 and RHDV2, formulated as a suspension for injection with aluminum hydroxide adjuvant. Its mechanism is prophylactic induction of protective humoral immunity against lagovirus capsid antigens, with onset of immunity at about 1 week after vaccination and duration of immunity of 1 year.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fatrovax RHD.